A nurse-led chronic disease management clinic in the urology department of a tertiary hospital recorded 14,013 outpatient registrations between July 2024 and September 2026, according to a single-center retrospective descriptive study using routinely collected service records. The clinic primarily supported long-term management of patients with prostate and bladder cancer while also providing specialty nursing services for other urological conditions. Its follow-up system marked 3,547 of 3,553 assigned tasks as successful, a task-level success rate of 99.83%. These figures describe service activity and record completion; the study did not measure whether the clinic improved clinical outcomes or economic performance.

The clinic was established in July 2024 within the hospital’s existing specialty nursing outpatient service framework. Its operating model included staffing and qualification requirements, professional training, clearly defined nursing responsibilities, physician–nurse collaboration, standardized procedures, information-system support and quality management. Nurses worked within their authorized scope of practice, while urologists participated in medical assessment and treatment decisions when required. The service had four reported components: patient assessment and follow-up planning; treatment follow-up and adverse-event monitoring; rehabilitation guidance and health promotion; and assistance with healthcare policies and basic nursing care.

Monthly registrations increased from 147 in July 2024 to a peak of 710 in August 2026, with fluctuations during the reporting period. Total registration fees were CNY 152,758. The clinic delivered 14,246 prostate cancer-related injections, 3,523 urinary catheterizations, 2,777 intravesical instillation procedures and 2,142 urinary catheter removals. It also assisted patients with prostate or bladder cancer in applying for outpatient chronic and special disease insurance benefits. The study reports these counts as routine service activities, but it did not compare the procedures with those delivered elsewhere or evaluate their individual clinical effects.

Follow-up management was integrated into the clinic’s information system, which contained records for 1,111 patients. Of these, 953 patients had been followed up and 951 had successful follow-up records. Nurses also executed 3,553 follow-up tasks, of which 3,547 were successful, corresponding to the reported 99.83% task-level rate. The descriptive data do not specify the duration or effectiveness of patient follow-up, assess whether missed contacts influenced treatment adherence or health outcomes, or establish how the results would compare with another care model.

Because the research covered one tertiary hospital and relied on routinely collected records, it cannot establish how the clinic would operate in smaller facilities, under different staffing arrangements or in other health systems. The findings offer a documented example of a nurse-led outpatient service with defined responsibilities, standardized workflows, follow-up documentation and collaboration with urologists. The authors stated that further research is needed to evaluate the model’s clinical outcomes and economic implications. Accordingly, the registration growth, procedural workload and high proportion of completed follow-up tasks should be interpreted as descriptions of implementation and recorded service delivery, not as evidence of improved survival, fewer complications, lower costs or other patient benefits.

Subject of Research: Operation and service activity of a nurse-led chronic disease management clinic in hospital urology

Article Title: Development and implementation of a nurse-led chronic disease management clinic in the urology department of a tertiary hospital: a descriptive study

Article References: Liu, C., Xia, Y., Jia, X., Wang, R., Li, T., Ma, Y., & Long, H. (2026). Development and implementation of a nurse-led chronic disease management clinic in the urology department of a tertiary hospital: a descriptive study. BMC Nursing. https://doi.org/10.1186/s12912-026-05566-z

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05566-z

Keywords: nurse-led care, urology, outpatient nursing, chronic disease management, prostate cancer, bladder cancer, patient follow-up, service implementation, descriptive study, Development, implementation, nurse-led

In a groundbreaking advancement in the treatment of metastatic urothelial cancer, a recent clinical trial has explored the synergistic potential of combining immune checkpoint inhibitors tremelimumab and durvalumab with the chemotherapeutic agent paclitaxel. This phase I/II ICRA trial, published in the prestigious Nature Communications, offers compelling evidence that dual immune modulation with or without chemotherapy may redefine therapeutic paradigms for this challenging malignancy. The innovative study meticulously investigates the safety profile, optimal dosing, and preliminary efficacy signals of these agents when administered simultaneously, charting a promising new course in oncologic therapeutics.

Urothelial carcinoma, predominantly affecting the bladder, represents a formidable oncological challenge due to its aggressive nature and propensity for metastasis upon progression. While immune checkpoint inhibitors have revolutionized cancer care by unleashing the host’s immune system against tumor cells, their efficacy as monotherapy in advanced urothelial cancer remains variable. Tremelimumab, a monoclonal antibody targeting CTLA-4, and durvalumab, an anti-PD-L1 antibody, function by disrupting distinct immunosuppressive pathways that tumors exploit to evade immune detection. The rationale behind combining these agents with paclitaxel—a cytotoxic drug known for interfering with microtubule dynamics—lies in the complementary mechanisms that might potentiate antitumor responses.

The trial enrolled patients with histologically confirmed metastatic urothelial cancer who had exhausted or were ineligible for standard therapeutic options. Participants received varying regimens comprising tremelimumab alone, tremelimumab plus durvalumab, and either combination with paclitaxel. This design sought to delineate the safety thresholds and dose-limiting toxicities while enabling exploratory analyses of clinical outcomes such as progression-free survival and objective response rates. Detailed immune profiling and biomarker assessments accompanied the clinical evaluations to decipher correlates of response and resistance.

Initial data reveal that the combination treatments are generally well tolerated, with adverse events consistent with known profiles of checkpoint inhibitors and chemotherapy. Immune-related adverse events—such as dermatitis, colitis, and endocrinopathies—were manageable within established guidelines, emphasizing the importance of vigilant monitoring and timely intervention. Importantly, no unexpected synergistic toxicities emerged, suggesting that these agents can be safely coadministered without exacerbating systemic toxicity.

From an efficacy standpoint, tremelimumab combined with durvalumab and paclitaxel demonstrated encouraging antitumor activity, surpassing response rates historically observed with any single agent in this patient cohort. Objective responses included significant tumor burden reductions, with some patients experiencing durable disease stabilization or partial remission. Notably, the addition of paclitaxel appeared to enhance immunogenic cell death, potentially promoting antigen presentation and T-cell activation, thus amplifying the therapeutic window of the checkpoint blockade.

Correlative translational studies provided insights into the immunological milieu shaping treatment responses. Tumor biopsies and peripheral blood analyses highlighted increased infiltration of CD8+ cytotoxic T lymphocytes and a concomitant decrease in immunosuppressive regulatory T cells in responders. Furthermore, upregulation of interferon-gamma signaling pathways and enhanced expression of antigen processing machinery were observed, aligning with the hypothesis that chemotherapy-induced immunogenicity synergizes with checkpoint inhibition to invigorate antitumor immunity.

Another pivotal observation was the heterogeneity in patient outcomes, underscoring the necessity for biomarker-driven patient stratification. Molecular profiling identified tumor mutational burden and PD-L1 expression levels as potential predictive biomarkers, although their roles require further validation. Intriguingly, emerging evidence suggests that tumor microenvironment features—such as cytokine profiles and myeloid cell populations—may also influence responsiveness, opening new avenues for personalized immunotherapy approaches.

The trial’s phased escalation design allowed for adaptive modifications based on interim results, optimizing dosing regimens to balance efficacy and safety. These methodological strengths enhance the reliability of conclusions drawn and set a precedent for future combination trials in urothelial carcinoma and beyond. Additionally, pharmacokinetic analyses confirmed that neither agent significantly altered the metabolism of the others, supporting their compatibility in combination therapies.

This landmark investigation contributes critical knowledge to the evolving landscape of bladder cancer treatment by demonstrating how rationally designed combinations of immune checkpoint inhibitors and chemotherapies can elicit potent antitumor effects in metastatic disease. Given the historically poor prognosis for advanced urothelial cancer, these findings herald a new era where multi-agent immunomodulation may offer renewed hope for patients. However, broader phase III studies will be essential to confirm survival benefits and thoroughly characterize long-term safety.

Moreover, the translational components embedded within this study exemplify the growing trend towards integrating laboratory science with clinical oncology. Such integrative approaches are crucial for unraveling the complex interplay between tumor biology and therapeutic interventions, ultimately facilitating the development of more effective, tailored treatments. The ICRA trial represents an exemplar of precision medicine in action, advancing beyond one-size-fits-all approaches towards nuanced, biomarker-informed strategies.

While the current research focuses on metastatic urothelial carcinoma, the implications extend to other malignancies where immune evasion is a critical obstacle. The dual blockade of CTLA-4 and PD-L1 pathways in concert with chemotherapeutic agents may prove universally applicable, prompting parallel investigations across diverse cancer types. Furthermore, understanding the mechanisms that underlie response and resistance could inform the design of next-generation immunotherapies, including combination regimens incorporating novel agents such as oncolytic viruses, vaccines, or cell-based therapies.

In the broader context of cancer immunotherapy, the trial reinforces the concept that combining immune checkpoint inhibitors with traditional cytotoxic chemotherapy can create a more hostile environment for cancer cells while simultaneously activating immune effector functions. This synergistic interaction leverages the strengths of both modalities: chemotherapy disrupts tumor cell replication and induces immunogenic cell death, while checkpoint inhibitors relieve inhibitory signals that dampen T-cell activity. Together, they orchestrate a multifaceted assault on cancer.

The success of this approach depends heavily on careful patient selection, vigilant management of immune-related adverse events, and comprehensive biomarker development. As immune therapies increasingly become standard in oncology, multidisciplinary collaborations between clinicians, immunologists, and computational biologists will be vital to fully harness their potential. The ICRA trial epitomizes such collaborative effort, merging clinical expertise with cutting-edge immunological research.

In summary, the phase I/II ICRA trial investigating tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer delineates a compelling therapeutic strategy blending checkpoint blockade and chemotherapy. It underscores important principles regarding safety, efficacy, and mechanistic synergy while illuminating paths for future exploration. As the oncology community eagerly awaits results from larger confirmatory studies, this trial stands as a milestone in the continuous quest to improve outcomes for patients facing this formidable disease.

Subject of Research: Combination immunotherapy with tremelimumab and durvalumab alongside paclitaxel chemotherapy in metastatic urothelial cancer.

Article Title: Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

Article References: Einerhand, S.M.H., Ali, H., Wong, S.Q. et al. Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74570-3

Image Credits: AI Generated